Actively Recruiting
Randomized, Placebo-Controlled Study Comparing 2LEBV4 and 2LXFS4 Capsules for Fatigue in Epstein-Barr Virus Infection
Led by Labo'Life · Updated on 2026-08-31
88
Participants Needed
8
Research Sites
1 weeks
Total Duration
AI-Summary
What This Trial Is About
Epstein-Barr Virus EBV infects about 95% of adults worldwide and can lead to various conditions including infectious mononucleosis, chronic fatigue syndrome, and certain malignancies. Most EBV infections do not show symptoms due to effective immune responses. This study aims to evaluate the effects of two drugs, 2LEBV4 and 2LXFS4, compared to placebo in reducing fatigue and other symptoms associated with EBV infection. Participants will take one capsule daily of either 2LEBV4, 2LXFS4, or placebo for six continuous months. The capsules are taken sequentially according to their number on the blister pack. This treatment schedule is the same for both drugs and placebo, ensuring a consistent dosing routine during the study period. Throughout the six months, participants will be monitored for fatigue levels using the Multidimensional Fatigue Inventory-20 questionnaire and other EBV-related symptoms. Researchers will compare symptom changes and immune cell markers between treatment and placebo groups. Safety will be assessed by recording any adverse events. The studys total duration allows for comprehensive evaluation of treatment effects on EBV symptoms.
CONDITIONS
Brief Title
Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
Research Team
C
Charlotte BOLLE
L
Laura FERTE
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here